Artificial Intelligence-Driven Designer Drug Combinations: From Drug Development to Personalized Medicine

SLAS Technol. 2019 Feb;24(1):124-125. doi: 10.1177/2472630318800774. Epub 2018 Sep 24.


Artificial intelligence holds great promise in transforming how drugs are designed and patients are treated. In a study recently published in Science Translational Medicine, a unique artificial intelligence platform makes efficient use of small experimental datasets to design new drug combinations as well as identify the best drug combinations for specific patient samples. This quadratic phenotypic optimization platform (QPOP) does not rely on previous assumptions of molecular mechanisms of disease, but rather uses system-specific experimental data to determine the best drug combinations for a specific disease model or a patient sample. In this commentary, we explore how QPOP was applied toward multiple myeloma in the study. We also discuss how this study demonstrates the potential for applications of QPOP toward improving therapeutic regimen design and personalized medicine.

Keywords: artificial intelligence; cancer; drug development; personalized medicine.

Publication types

  • Comment

MeSH terms

  • Artificial Intelligence
  • Drug Combinations
  • Drug Development
  • Humans
  • Multiple Myeloma*
  • Precision Medicine*


  • Drug Combinations